Clinical trial NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
Official title: A Randomised, Comparative, Prospective, Multicentre Study of the Efficacy of Nivolumab + Ipilimumab Versus Pazopanib Alone in Patients With Metastatic or Unresectable Advanced Sarcoma of Rare Subtype (RAR-Immune)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Sarcoma
Keywords: Sarcoma of rare subtype
Metastatic sarcoma
Unresectable advanced sarcoma
Nivolumab
Ipilimumab
Randomization
Pazopanib
Progression free-survival
Best Overall Response
Objective response rate
Duration of response
Time to treatment failure
Overall survival
Quality of Life
Tolerance profile
Lead sponsor: Centre Leon Berard
Sponsor class: OTHER
First posted: 2021-02-05
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard therapy does not exist or is not considered appropriate by the Investigator.

In the experimental arm, patients will receive the combination of Nivolumab + Ipilimumab for a maximum of 24 months, whereas in the control arm, patients will receive Pazopanib alone.

The purpose of the study is to know if the combination of nivolumab + ipilimumab can be more efficient than Pazopanib in terms of Progression-Free Survival.

Detailed description: This is a randomized open label, comparative, prospective, multicentre phase III study.

The patients who meet the eligibility criteria will be randomly assigned (1:1) into one of the following treatments groups:

* Experimental arm: Nivolumab + Ipilimumab (24 months maximum)
* Control arm: Pazopanib alone (24 months maximum)

A randomization procedure will be used to obtain a balanced distribution of stratifications factors:

* The number of previous lines of treatment in advanced/metastatic setting: ≤1 line or \>1 line (a treatment line is defined as a treatment initiation whatever the reason)
* The lymphocytes count at baseline: \<1 g/L or ≥1 g/L.

After their eligibility has been confirmed, patients will be treated with:

* The combination of Nivolumab + Ipilimumab for 4 cycles. After completion of 4 cycles with Ipilimumab, patients continue receiving nivolumab IV (480 mg Q4W) in the absence of disease progression or unacceptable toxicity. A cycle is defined as a 6-weeks period.
* Or Pazopanib until disease progression or unacceptable toxicity. The planned treatment duration in both arm is maximum 24 months.

After the completion of treatment, patients will be followed up within 30 days after the last study treatment administration. The survival and disease status will be updated for all patients at the time of the end of the study.

The overall end of the study will be the Last Patient Last Visit (LPLV), defined as the End Of Treatment (EOT) visit of the last active patient.

Eligibility criteria: Inclusion Criteria:

I1. Age ≥ 18 years at the day of consenting to the study;

I2. Only histologically confirmed sarcoma of rare subtype, defined as one of the following subtypes:

* Angiosarcoma (AS)
* Alveolar Soft Part Sarcoma (ASPS)
* Clear Cell Sarcoma (CCSA)
* Desmoplastic Small Round Cell Tumour (DSRCT)
* Sclerosing Epithelioid Fibrosarcoma (SEF)
* Perivascular Epithelioid Cell Tumour (PEComa)
* Intimal sarcoma (IS)
* Extraskeletal Myxoid Chondrosarcoma (EMC)
* Solitary Fibrous Tumour (SFT)
* Epithelioid HemangioEndothelioma (EHE)
* Inflammatory Myofibroblastic Tumour (IMT)
* Epithelioid sarcoma (ES)
* FibroSarcoma (FS)
* SMARCA-4 deficient sarcoma
* Malign Peripheral Nerve Sheath Tumours (MPNST)
* Chordoma;

I3. Metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator;

I4. Measurable disease as per the RECIST version 1.1;

I5. Previously treated with anthracycline-based regimen except for whom standard therapy does not exist or is not considered appropriate by the Investigator: inclusion in first line is allowed (randomisation will be stratified according to the number of previous treatment lines);

I6. Performance Status (ECOG) of 0 or 1;

I7. Patients must have an adequate organ and bone marrow function at baseline;

* Absolute neutrophil count (ANC) ≥ 1.0 x 10 G/L
* Platelets ≥ 100 x 10 G/L
* Haemoglobin ≥ 9 g/dL (without transfusion within 7 days)
* Serum creatinine OR Calculated creatinine clearance as per MDRD or CKD-EPI formula ≤ 1.5 upper limit of normal (ULN) OR ≥ 40 mL/min /1.73m2
* Serum total bilirubin ≤ 1.5 ULN OR Direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5 ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3ULN is acceptable).
* AST and ALT ≤ 3 ULN
* International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) ≤ 1.5 ULN

I8. Women of childbearing potential must have a negative serum pregnancy test within 7 days before C1D1.

I9. Women of childbearing potential must agree to use 1 highly effective form of contraception from the time of the negative pregnancy test up to 3 months after the last dose of study drugs.

I10. Ability to understand and willingness for follow-up visits;

I11. Covered by a medical insurance;

I12. Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.

Exclusion Criteria:

E1. Concurrent use of any other approved or investigational antineoplastic agent;

E2. Prior or concurrent treatment with any antibody targeting PD1, PDL1, PDL2 or CTLA4;

E3. Prior treatment with pazopanib;

E4. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.

Note:

* Asymptomatic patients with treated CNS lesions are eligible.
* Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan;

E5. Patients using, or requirement to use while on the study, or not respecting the minimal wash-out period of medications listed below:

Forbidden concomitant medications and minimal wash-out period before Cycle 1 Day1

* Any approved anti-cancer systemic treatment including chemotherapy, hormonotherapy, biological therapy, or immunotherapy : 2 weeks
* Any investigational agents : 4 weeks
* Radiotherapy Note: palliative radiotherapy on non-target lesions is allowed. : 3 weeks
* Surgery
* Major surgical procedure, open biopsy, or significant traumatic injury : 4 weeks
* Abdominal surgery, abdominal interventions or significant abdominal traumatic injury : 60 days
* Live vaccines. Note: Influenza vaccination should be given during influenza season. Patients must not receive live attenuated influenza vaccine (e.g., FluMist®) : 4 weeks
* Systemic immunostimulatory agents, including but not limited to IFN-α, IFN-γ, or IL-2 : 4 weeks
* Immunosuppressive medication (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) with the exceptions of intranasal, inhaled, or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone (or 0.1mg/kg for pediatric patients), or an equivalent corticosteroid :2 weeks
* P-gp inhibitors : None
* Strong or moderate inhibitors of CYP3A4 : None
* Strong CYP3A4 inducers : None
* Oral or IV antibiotics :2 weeks

Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection, pneumocystis or chronic obstructive pulmonary disease exacerbation) are eligible.

E6. History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following exceptions:

* patients with a history of autoimmune-related hypothyroidism who are on stable thyroid replacement hormone therapy,
* patients with controlled Type 1 diabetes mellitus,
* patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are eligible provided that they meet the following conditions:

  * Rash must cover less than 10% of body surface area (BSA).
  * Disease is well controlled at baseline and only requiring low potency topical steroids.
  * No acute exacerbations of underlying condition within the previous 12 months requiring psoralen plus ultraviolet A radiation (PUVA), methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids;

E7. Patients with HIV, active B or C hepatitis infection, or any other active infection.

E8. Patients with active tuberculosis;

E9. Prior allogeneic bone marrow transplantation or solid organ transplant for another malignancy in the past;

E10. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan;

E11. Patients with a high-risk of hemorrhage or history of coagulopathy;

E12. Any contraindication to nivolumab, to ipilimumab or to pazopanib according to the Summary of Product Characteristics of each drug;

E13. History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years;

E14. Patient under tutorship or curatorship or deprived of liberty;

E15. Pregnant or breast-feeding woman

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: up to 36 months
Secondary outcomes:
measure: Best Overall Response (BOR)
timeFrame: up to 36 months
measure: Objective Response Rate (ORR)
timeFrame: up to 36 months
measure: Duration of Response (DOR)
timeFrame: up to 36 months
measure: Time to Treatment Failure (TTF)
timeFrame: up to 36 months
measure: Overall Survival (OS)
timeFrame: up to 36 months
measure: Quality of Life (QoL)
timeFrame: up to 36 months
measure: Tolerance profile
timeFrame: up to 36 months
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Institut de cancérologie Strasbourg Europe
state: Bas-Rhin
city: Lyon
country: France
facility: Centre Léon Bérard
state: Rhône
city: Besançon
country: France
facility: Hôpital Jean Minjoz
city: Bordeaux
country: France
facility: Institut Bergonié
city: Dijon
country: France
facility: Centre Georges François Leclerc
city: Lille
country: France
facility: Centre Oscar Lambret
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Paris
country: France
facility: Hôpital Cochin
city: Poitiers
country: France
facility: CHU de Poitiers
city: Rennes
country: France
facility: Centre Eugène Marquis
city: Toulouse
country: France
facility: Institut Claudius Regaud - IUCT Oncopole
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
References: